Revista de vasculitis

Vasculitis and COVID-19: Insights from Recent Studies

Abstract

Alex Jerome*

Leukocytoclastic vasculitis, similar as IgAV, is a little vessel vasculitis set apart by resistant complex-intervened harm. It shows up as erythematous macules with obvious purpura showing up respectively on lower limits and posterior. Nonetheless, dissimilar to IgAV, it commonly influences grown-ups, albeit different gatherings are additionally in danger. Then again, Kawasaki infection is an overwhelmingly medium-vessel vasculitis that fundamentally influences kids matured five years or more youthful. Patients normally present with fever, rash, and enlarged hands and feet. Whenever left untreated, it might cause heart confusions and even demise. Vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels, has posed unique challenges during the COVID-19 pandemic. Patients with vasculitis often require immunosuppressive therapies, making them a vulnerable population to infections. This article provides an overview of recent studies and insights into the intersection of vasculitis and COVID-19, addressing the impact of the virus on vasculitis patients, potential associations, and strategies for managing these complex conditions. Patients with vasculitis are commonly treated with immunosuppressive drugs to manage their condition.